DXA023-G017

DXA023-G017: sourced facts only. name: "The protein binding affinities of both DXA023 and DXA023-G017 to PD-1 and VEGF were assessed by ELISA." [DOI:10.1158/1538-7445.am2025-2864]; target: "The protein binding affinities of both DXA023 and DXA023-G017 to PD-1 and VEGF were assessed by ELISA." [DOI:10.1158/1538-7445.am2025-2864]; developer: "Hangzhou DAC Biotechnology Co., Ltd., Hangzhou, China." [DOI:10.1158/1538-7445.am2025-2864]; modality: "DXA023-G017, a dual-blocking anti-PD-1/VEGF bispecific conjugate, demonstrates impressive antitumor efficacy in a mouse tumor model, providing robust support for its clinical development as a treatment for various advanced solid tumors." [DOI:10.1158/1538-7445.am2025-2864]; stage: "Furthermore, DXA023-G017 exhibits superior antitumor efficacy compared to DXA023 in the HCC827-PBMC mouse model." [DOI:10.1158/1538-7445.am2025-2864]